Danaher Corporation (DHR)vsFresh2 Group Ltd (FRES)
DHR
Danaher Corporation
$196.22
-0.16%
HEALTHCARE · Cap: $125.93B
FRES
Fresh2 Group Ltd
$0.85
0.00%
HEALTHCARE · Cap: $2.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 147762% more annual revenue ($25.11B vs $16.98M). DHR leads profitability with a 16.0% profit margin vs 0.0%. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
FRES
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$196.22
$78.34 premium
Intrinsic value data unavailable for FRES.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bull Case : FRES
The strongest argument for FRES centers on Price/Book, Debt/Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : FRES
The primary concerns for FRES are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
DHR profiles as a mature stock while FRES is a value play — different risk/reward profiles.
FRES carries more volatility with a beta of 1.28 — expect wider price swings.
DHR is growing revenue faster at 5.5% — sustainability is the question.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (66/100 vs 33/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Fresh2 Group Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?